Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 220

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

CD 19‐CAR engineered NK‐92 cells are sufficient to overcome NK cell resistance in B‐cell malignancies

Open access
Romanski, Annette, Uherek, Christoph, Bug, Gesine, Seifried, Erhard, Klingemann, Hans, Wels, Winfried S., Ottmann, Oliver G., Tonn, Torsten · 2016 · Journal of Cellular and Molecular Medicine

Abstract

Many B‐cell acute and chronic leukaemias tend to be resistant to killing by natural killer (NK) cells. The introduction of chimeric antigen receptors (CAR) into T cells or NK cells could potentially overcome this resistance. Here, we extend our previous observations on the resistance of malignant lymphoblasts to NK‐92 cells, a continuously growing NK cell line, showing that anti‐CD 19‐CAR (α CD 19‐CAR) engineered NK‐92 cells can regain significant cytotoxicity against CD 19 positive leukaemic cell lines and primary leukaemia cells that are resistant to cytolytic activity of parental NK‐92 cells. The ‘first generation’ CAR was generated from a scFv (CD 19) antibody fragment, coupled to a flexible hinge region, the CD 3ζ chain and a Myc‐tag and cloned into a retrovirus backbone. No difference in cytotoxic activity of NK‐92 and transduced α CD 19‐CAR NK‐92 cells towards CD 19 negative targets was found. However, α CD 19‐CAR NK‐92 cells specifically and efficiently lysed CD 19 expressing B‐precursor leukaemia cell lines as well as lymphoblasts from leukaemia patients. Since NK‐92 cells can be easily expanded to clinical grade numbers under current Good Manufactoring Practice (cGMP) conditions and its safety has been documented in several phase I clinical studies, treatment with CAR modified NK‐92 should be considered a treatment option for patients with lymphoid malignancies.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/jcmm.12810

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 4 references

Cited by

See all 220

Metadata

Authors
Romanski, A., Uherek, C., Bug, G., Seifried, E., Klingemann, H., Wels, W. S., Ottmann, O. G., & Tonn, T.
Venue
Journal of Cellular and Molecular Medicine
Publisher
Wiley
Published
2016-03-23
Volume
20
Issue
7
Pages
1287-1294
ISSN
  • 1582-1838 (ISSN-L)
  • 1582-4934
OpenAlex
W2311158642
Cited by
220
References
4
FWCI
10.20
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: CD 19‐CAR engineered NK‐92 cells are sufficient to overcome NK cell resistance in B‐cell malignancies. https://app.cochat.ai/papers/10.1111/jcmm.12810
The paper
Romanski, A., Uherek, C., Bug, G., Seifried, E., Klingemann, H., Wels, W. S., Ottmann, O. G., & Tonn, T. (2016). CD 19‐CAR engineered NK‐92 cells are sufficient to overcome NK cell resistance in B‐cell malignancies. Journal of Cellular and Molecular Medicine. https://doi.org/10.1111/jcmm.12810

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.